These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10394873)

  • 1. Ferric ammonium citrate as a positive bowel contrast agent for MR imaging of the upper abdomen. Safety and diagnostic efficacy.
    Kivelitz D; Gehl HB; Heuck A; Krahe T; Taupitz M; Lodemann KP; Hamm B
    Acta Radiol; 1999 Jul; 40(4):429-35. PubMed ID: 10394873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive bowel contrast agent for MR imaging of the abdomen: phase II and III clinical trials.
    Patten RM; Lo SK; Phillips JJ; Bowman SC; Glazer GM; Wall SD; Bova JG; Harris RD; Wheat RL; Johnson CD
    Radiology; 1993 Oct; 189(1):277-83. PubMed ID: 8372205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MR imaging of the gastrointestinal tract with i.v., gadolinium and diluted barium oral contrast media compared with unenhanced MR imaging and CT.
    Low RN; Francis IR
    AJR Am J Roentgenol; 1997 Oct; 169(4):1051-9. PubMed ID: 9308464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical value of ferric ammonium citrate: a positive oral contrast agent for T1-weighted MR imaging of the upper abdomen.
    Malcolm PN; Brown JJ; Hahn PF; Stillman AE; Li KC; Kawamura Y; Tanaka T; Noel JK; Molony BA; Johnson MF; Hildebolt CF
    J Magn Reson Imaging; 2000 Nov; 12(5):702-7. PubMed ID: 11050639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large scale clinical evaluation of bowel contrast agent containing ferric ammonium citrate in MRI.
    Hirohashi S; Uchida H; Yoshikawa K; Fujita N; Ohtomo K; Yuasa Y; Kawamura Y; Matsui O
    Magn Reson Imaging; 1994; 12(6):837-46. PubMed ID: 7968283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dilute oral iron solutions as gastrointestinal contrast agents for magnetic resonance imaging; initial clinical experience.
    Wesbey GE; Brasch RC; Goldberg HI; Engelstad BL; Moss AA
    Magn Reson Imaging; 1985; 3(1):57-64. PubMed ID: 3923293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of oral contrast agents for abdominal magnetic resonance imaging.
    Kraus BB; Rappaport DC; Ros PR; Torres GM
    Magn Reson Imaging; 1994; 12(6):847-58. PubMed ID: 7968284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OMR, a positive bowel contrast agent for abdominal and pelvic MR imaging: safety and imaging characteristics.
    Patten RM; Moss AA; Fenton TA; Elliott S
    J Magn Reson Imaging; 1992; 2(1):25-34. PubMed ID: 1623278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multisite phase III study of the safety and efficacy of a new manganese chloride-based gastrointestinal contrast agent for MRI of the abdomen and pelvis.
    Small WC; DeSimone-Macchi D; Parker JR; Sukerkar A; Hahn PF; Rubin DL; Zelch JV; Kuhlman JE; Outwater EK; Weinreb JC; Brown JJ; de Lange EE; Woodward PJ; Arildsen R; Foster GS; Runge VM; Aisen AM; Muroff LR; Thoeni RF; Parisky YR; Tanenbaum LN; Totterman S; Herfkens RJ; Knudsen J; Bernardino ME
    J Magn Reson Imaging; 1999 Jul; 10(1):15-24. PubMed ID: 10398973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Optimization of dosage and exam technique in the use of oral contrast media in magnetic resonance].
    Broglia L; Tortora A; Maccioni F; Arpesani R; Marcelli G; Ascarelli A; Rossi P
    Radiol Med; 1999 May; 97(5):365-70. PubMed ID: 10432968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Elimination of bowel fluid artifact on abdominal DWI using oral contrast agent ferric ammonium citrate].
    Takahashi T; Kato K; Nishizawa T; Nakazawa Y
    Nihon Hoshasen Gijutsu Gakkai Zasshi; 2008 May; 64(5):573-8. PubMed ID: 18509218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [High concentration ferric ammonium citrate (FAC) solution as a negative bowel contrast agent].
    Takahara T; Yoshikawa T; Saeki M; Nosaka S; Shimoyamada K; Nakajima Y; Ishikawa T
    Nihon Igaku Hoshasen Gakkai Zasshi; 1995 May; 55(6):425-6. PubMed ID: 7617470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Oral contrast media for magnetic resonance tomography of the abdomen. 1. Comparative animal studies of positive and negative contrast media].
    Laniado M; Kaminsky S; Semmler W; Weinmann HJ; Zurth C; Claussen C
    Rofo; 1987 Sep; 147(3):325-32. PubMed ID: 2445010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of and sequence choice for two oral contrast agents used during MR imaging.
    Grubnic S; Padhani AR; Revell PB; Husband JE
    AJR Am J Roentgenol; 1999 Jul; 173(1):173-8. PubMed ID: 10397122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: results of a Phase III clinical trial.
    Rubin DL; Desser TS; Semelka R; Brown J; Nghiem HV; Stevens WR; Bluemke D; Nelson R; Fultz P; Reimer P; Ho V; Kristy RM; Pierro JA
    J Magn Reson Imaging; 1999 Feb; 9(2):240-50. PubMed ID: 10077020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [MR imaging of colonic cancer with retrograde administration of contrast material containing ferric ammonium citrate].
    Mizuguchi M; Matsuo Y; Fukahori T; Kudo S
    Nihon Igaku Hoshasen Gakkai Zasshi; 1995 Dec; 55(15):1063-5. PubMed ID: 8587850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary evaluation of iron phytate (inositol hexaphosphate) as a gastrointestinal MR contrast agent.
    Unger EC; Fritz TA; Palestrant D; Meakem TJ; Granstrom P; Gatenby RA
    J Magn Reson Imaging; 1993; 3(1):119-24. PubMed ID: 8428077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MR enteroclysis using iron oxide particles (ferristene) as an endoluminal contrast agent: an open phase III trial.
    Boraschi P; Braccini G; Gigoni R; Cartei F; Perri G
    Magn Reson Imaging; 2004 Oct; 22(8):1085-95. PubMed ID: 15527995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral magnetic particles as a contrast agent for MR imaging of the abdomen. A phase III clinical trial.
    Vlahos L; Gouliamos A; Kalovidouris A; Athanasopoulou A; Kotoulas G; Lygidakis N; Liaou A; Matsaidonis D; Papavasiliou C
    Hepatogastroenterology; 1994 Feb; 41(1):82-5. PubMed ID: 8175124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [MR imaging oral contrast agent mixed with milk for the small intestine].
    Hirohashi S; Hirohashi R; Uchida H; Kitano S; Tanaka M; Matsuo N; Ohishi H
    Nihon Igaku Hoshasen Gakkai Zasshi; 1994 Jul; 54(8):784-8. PubMed ID: 8072869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.